Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Solvay said that its cholesterol drug fenofibrate significantly reduced the need for treatment of the main causes of vision loss in patients with type 2 diabetes in a study published in the Lancet.
Subscribe to our email newsletter
The study shows that fenofibrate decreases the need for laser therapy for diabetic eye disease by more than 30%. In addition to reducing the need for laser therapy in the overall population, fenofibrate showed, in a substudy of approximately 1,000 patients with pre-existing eye disease, a significant reduction in the progression of the disease.
Additional results from the fenofibrate intervention and event lowering in diabetes study show that fenofibrate significantly decreased the risk of non-traumatic amputations. Earlier data demonstrated that fenofibrate also significantly reduces microalbuminuria, a marker of the risk of progressive renal disease.